Skip to main content
Premium Trial:

Request an Annual Quote

ImaGenes to Offer Fasteris Sequencing Services in Germany and Austria

NEW YORK (GenomeWeb News) – Genomic service firms ImaGenes and Fasteris said today that they have entered into a partnership to provide next-generation sequencing services in Germany and Austria.
 
Under the terms of the agreement, ImaGenes of Berlin, Germany, will act as a local distributor for Fasteris’ sequencing services in Germany and Austria. ImaGenes, founded in 2007 as a spin-off from the German Resource Center for Genome Research, specializes in microarray-based genomic services.
 
Fasteris, based in Geneva, Switzerland, offers a range of sequencing services based on the Illumina Genome Analyzer platform, including small RNA, ChIP-Seq, and transcriptome analysis; gene expression profiling; de novo sequencing; and whole-genome or targeted re-sequencing for the detection of genetic variants.
 
Fasteris said that it has developed bar-coding protocols for preparing genomic, small RNA, or gene expression samples and has installed a paired-end module for the Illumina system that “facilitates de novo sequence assembly and identification of variants such as insertions or deletions.”
 
Steffen Hennig, director of bioinformatics and services at ImaGenes, said in a statement that the addition of Fasteris' sequencing technology to its offerings will provide the firm with new genomic or transcriptome sequence information that it can use to design new microarrays.
 
He added that the company also plans to offer SAGE and CAGE analyses on the Fasteris sequencer, “adding a new dimension to studies of transcript regulation.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more